Julien Bergeron

We are interested in exploiting recent developments in AI-driven protein design, to modify naturally occurring proteins to acquire new properties, for biomedical applications. We are particularly interested in exploiting ATP-driven protein oligomerization, to design synthetic protein-based nanoparticles for targeted drug delivery. A spin-out biotechnology company, Prosemble (www.prosemble.bio) has been developped to pursue this specific application of our protein design approach.